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TO THE EDITOR
Idiopathic myelofibrosis (IMF) is a chronic myeloproliferative disorder characterized by bone marrow fibrosis, extramedullary hematopoiesis, splenomegaly, anemia and peripheral blood leukoerythroblastosis. The stromal proliferation is a reactive phenomenon, caused by intramedullary release of cytokines such as platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, epidermal growth factor and calmodulin. 1 Thalidomide retains antiangiogenic, immunomodulatory and cytokine regulatory properties and these activities have suggested a potential therapeutic role in IMF. However, the efficacy of thalidomide is demonstrated in a few studies, with variable grades of response, more frequently minor. [2] [3] [4] [5] [6] Recombinant human erythropoietin (rHuEPO) has been used for the treatment of transfusion-dependent anemia, and recent results suggest that patients with low basal serum erythropoietin and low transfusional dependency have a better response. 7 A synergistic effect of the two drugs in IMF, although possible, has, up to now, not been shown. We thus treated one patient with IMF, previously insensitive to erythropoietin and scarcely responsive to thalidomide, used as single drugs, with a sequential combination of erythropoietin and thalidomide.
A 63-year-old man was referred to our hospital presenting with a 6-year history of IMF. The diagnosis was made by standard criteria; 8 Philadelphia chromosome and bcr-abl rearrangement were absent. The peripheral blood picture was: Hb 9.1 g/l, leukocytes 6.5 Â 10 9 /l, platelets 101 Â 10 9 /l and spleen was 7 cm from the left costal margin. The level of serum erythropoietin was 70 mU/ml. Iron, transferrin and ferritin were 45, 343 and 68 mg/dl, respectively. RhuEPO was used for 3 months for anemia without improvement of hemoglobin level. To control the disease, the patient was treated with hydroxyurea (Hu) (500-1500 mg every other day) and the disease remained stable for 5 years, when fatigue increased. Hemoglobin was 9.7 g/l, leukocytes: 9.5 Â 10 9 /l, platelets: 97 Â 10 9 /l and the spleen had enlarged to 20 cm. A trephine biopsy showed a marked diffuse increase in reticulin fibers with hypocellular areas and coexistent hypercellular hemopoietic areas. Megakaryocytes were atypical and increased in number. Granulocytic precursors, p5 CD34+ cells and erythroblasts were present.
Therapy remained unchanged till 3 months later, when, due to peripheral blood leukocytosis, a treatment with Eldisine (1 fl every 2-3 weeks for 6 months) was attempted with success, in addition to Hu. Fatigue, however, increased, with a reduction of Hb levels (7.4 g/l) requiring transfusion support (2 U packed red blood cells per month) and of platelets (45x10 9 /l); at the same time, spleen size further increased (25 cm).
The patient was then started on oral thalidomide at an escalating dose from 100 mg to the maximum dose tolerated of 400 mg daily; the main side effects were constipation and fluid retention. Hu (500 mg/day) was continued.
After 8 months of combined thalidomide-Hu treatment, the grade of anemia, the level of platelets and the spleen size were unchanged. In an attempt to reduce the transfusion requirements, rHuEPO (twice weekly, 150 U/kg) was added, notwithstanding the previous unsuccessful attempt. The iron balance and the erythropoietin level were still normal. No other drugs, including steroids, were added. After 3 months of combined therapy, anemia and thrombocytopenia improved (hemoglobin: 10.3 g/l and platelets: 119 Â 10 9 /l). After 6 months, hemoglobin, platelets, hematocrit and leukocytes were, respectively, 15.5 g/l; 220 Â 10 9 /l; 50% and 23 Â 10 9 /l. Spleen size was reduced to 18 cm. RHuEPO was suspended; phlebotomies were then performed to reduce hematocrit under 50%; the doses of thalidomide and Hu were reduced respectively to 100 and 500 mg daily (see Figure 1) . A new bone marrow biopsy showed an increase in cellularity (85%), with a normal morphology for megakaryocytes and stable erythroblasts and granulocytic precursors, whereas, on the contrary, reticulin fibers were only slightly decreased.
Up to now, 30 months after the start of thalidomide and 22 months after the combined treatment with rHuEPO, the patient remains well, with normal blood counts and further reduced spleen size (12 cm). This is the first documented case in the literature in which thalidomide has been successfully used in combination with rHuEPO and Hu in IMF.
A polyclonal stromal proliferation, as well as bone marrow neovascularization (mediated by several cytokines) are the prominent features of IMF. It is known that thalidomide exerts antiangiogenic and anticytokine activity and may have a role in the treatment of patients affected by IMF. Elliott et al 5 reported that oral thalidomide, starting at a dose of 200 mg/day, achieved an improvement in anemia (20%), in bone marrow megakaryopoiesis (55%), correction of thrombocytopenia (80%), reduction in spleen size (25%) and/or decrease of bone marrow angiogenesis (22%) in a group of 15 patients affected by IMF. Barosi et al 2 showed quite similar results with a high rate of side effects using standard dosages of thalidomide (100-400 mg/day). We reported 6 that 12 patients with IMF in disease progression achieved a decrease of spleen size and an improvement of anemia, thrombocytopenia and leukocytosis using 100-600 mg daily of thalidomide.
On the other hand, RHuEPO has been used with limited and different response patterns in the treatment of anemia secondary to IMF. Rodriguez et al 7 showed that rHuEPO increases the hemoglobin level only in patients with low transfusion needs. Unfortunately, patients with high transfusion dependency did not respond to rHuEPO. Based on this, we added rHuEPO to thalidomide (plus a low dosage of Hu), hoping for a synergistic effect, in one patient with IMF in progression phase. Interestingly, the hemoglobin level and transfusion requests did not change until the introduction of rHuEPO in the treatment, as well as the number of platelets and the spleen size. It has to be remarked that rHuEPO resulted ineffective in a previous attempt performed 3 years before. A possible explanation could be an immunomodulatory effect determined by thalidomide on the release of cytokines and stromal proliferation, thus favoring the following effect of the combined treatment thalidomide-rHuEPO. Concerning the increase of platelet counts and decrease of spleen volume, it has been postulated as possibly mediated by a reduction in vascularity and angiogenesis, due to thalidomide, at the sites of extramedullary hemopoiesis as the spleen. 5 On the other hand, Barosi et al 2 suggested that thalidomide improves thrombocytopenia and splenomegaly probably exerting a myeloproliferative effect in IMF by increase of the number of CD34+ cells.
The combined treatment has not been able to reduce markedly the amount of reticulin fibers; however, it has to be underlined that bone marrow cellularity markedly increased, with normal morphology of megakaryocytes. Thus, the good response observed in our case suggests that thalidomide plus rHuEPO may be an option for IMF patients even with advanced disease, unresponsive to the drugs used as monotherapy. In particular, it might be a valid choice also in patients with a strongly increased marrow fibrosis and a suboptimal marrow reserve.
Biological and clinical studies are anyway warranted to better clarify the rationale of thalidomide therapy, the choice of agents active in combination and which subset of patients could benefit more by this treatment.
